WHO ICTRP trial
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in…
CTIS2024-511286-11-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-511286-11-00 |
|---|---|
| Public title | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors |
| Scientific title | - HFB-200301-01 |
| Primary sponsor | Hifibio Inc. |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): Yes Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | United States;China;Spain |
| Conditions | Advanced Solid Tumors MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Registration date | Apr 15, 2024 |
| Target size | 376 |
| Secondary IDs | NCT05238883;U1111-1303-8965;2021-006231-25 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: